Automation Anywhere Integrates with AWS to Showcase the Future of Human-Agent Collaboration
NEW YORK, July 16, 2025 /CNW/ -- At the AWS Summit New York City, Automation Anywhere, the leader in Agentic Process Automation (APA), and Amazon Web Services, Inc. (AWS), today announced an enhancement to its Automation Co-Pilot through a new integration with Amazon Q Business. Combining Amazon Q's enterprise-grade generative AI and Automation Anywhere's industry-first Process Reasoning Engine (PRE) enhances and amplifies the intuitive experience for business users. This combination enhances Automation Anywhere's Automation Co-Pilot's natural language interface which expediently turns intent into real outcomes. This enhancement to Automation Co-Pilot is also available today to developers and can be delivered as a standalone application or embedded into the primary application used by business users.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
16 minutes ago
- Globe and Mail
This Artificial Intelligence (AI) Stock Could Thrive Despite U.S.-China Trade Pressures
Key Points The U.S. and China are at odds over a range of issues, including trade imbalances and AI competition. The Trump administration tightened AI regulations related to China this year, and that's affected many companies. Nvidia is among the businesses impacted by AI sales restrictions to China, but it looks positioned to continue its success despite the challenges. 10 stocks we like better than Nvidia › The U.S. government's current trade tensions with China stretch back to President Donald Trump's first term. But the situation isn't about tariffs alone. The U.S. is competing with its trading partner for supremacy in artificial intelligence. This led to new export restrictions on the sale of AI chips to China on April 9. The updated regulations affect many tech businesses, including AI leader Nvidia (NASDAQ: NVDA). The company's sales of its popular graphics processing units (GPUs), powerful computer processors that have brought Nvidia success in the AI era, have been hurt by the federal government's export policies around such tech. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » Even so, several signs suggest Nvidia can continue to thrive despite the trade conflicts between the U.S. and China. Here is a look into Nvidia's potential for ongoing success despite the hurdles. The impact of China restrictions on Nvidia The frosty relations between the U.S. and China adversely affected Nvidia. The new export restrictions meant the company couldn't sell its AI chips earmarked for China, resulting in a $4.5 billion write-off for this unsold inventory in its fiscal first quarter, which ended April 27. China was responsible for $5.5 billion of Nvidia's $44.1 billion in Q1 revenue. This figure could have been higher, since the company was barred from shipping an additional $2.5 billion in AI products in Q1. Lost revenue isn't the only consequence. Nvidia CEO Jensen Huang declared, "The AI race is not just about chips. It's about which stack the world runs on. As that stack grows to include 6G and quantum, U.S. global infrastructure leadership is at stake." In other words, strengthening American leadership in AI depends on organizations around the world building AI infrastructure with U.S. technology platforms, such as Nvidia's proprietary compute unified device architecture (CUDA) software for customizing GPUs. The current trade restrictions limit this from happening, according to Huang. Nvidia's resilient business These hurdles are significant, yet Nvidia demonstrated that its business remains strong in the face of such challenges. For instance, despite the loss of sales in China, its $44.1 billion in Q1 revenue represented impressive 69% year-over-year growth. Its perseverance amid China sales setbacks is mirrored in Nvidia stock, which is up nearly 30% in 2025 through July 15, as shares hit a 52-week high of $172.40 on that date. Its soaring shares helped the company become the first to achieve a $4 trillion market cap. Trump congratulated Nvidia on its stock's performance. Huang has visited the White House several times, and the positive relationship he has cultivated with Trump gives Nvidia an edge amid trade pressures. In fact, the company recently announced plans to resume selling its AI chips to China, stating, "The U.S. government has assured Nvidia that licenses will be granted, and Nvidia hopes to start deliveries soon." Factors in Nvidia's favor Huang noted Nvidia's tenacity amid trade tensions, asserting, "Every single year there were rules and taxes and tariffs and policies and regulations, and we survived... and whatever it turns out to be, we'll make the best of it." The company's confidence in its future is illustrated in its fiscal Q2 outlook, which estimates $45 billion in revenue. This is a strong increase from the $30 billion made in the previous year. Nvidia's success to date is poised to continue even if its sales to China remain tepid. The U.S. is its largest source of revenue, contributing $20.7 billion of Q1's $44.1 billion. Moreover, the company's current AI platform, Blackwell, will soon make way for next-generation technology, Vera Rubin, due out in 2026. Vera Rubin is a superchip designed to transform how AI is integrated into supercomputers. Many organizations are rushing to build data centers for their AI systems with Nvidia's products. For example, European manufacturers are building an AI facility focused on boosting industrial manufacturing. This installation will require 10,000 Nvidia GPUs. And Facebook parent Meta Platforms is constructing several data centers reportedly using over 1 million Nvidia GPUs. This kind of hunger for Nvidia's AI products will continue to fuel the company's success for years to come. After all, industry forecasts estimate the AI market will expand from $244 billion in 2025 to $1 trillion by 2031. Although the extent to which its China business eventually recovers is uncertain, Nvidia is poised to remain a key AI player on the global stage, thanks to innovations such as CUDA and Vera Rubin. Its stock's price-to-earnings (P/E) ratio of 55 is getting up there but is still significantly lower than major rival Advanced Micro Devices 's 114. With many factors propelling Nvidia's business growth, its stock looks like a great long-term investment. Should you invest $1,000 in Nvidia right now? Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025
Globe and Mail
40 minutes ago
- Globe and Mail
Here's Why This $50 Healthcare Stock Could Be the Next $200 Winner
Key Points Exelixis' most important product should continue driving strong financial results through the end of the decade. The oncology specialist is working on a next-gen medicine that could be even better than its crown jewel. The midcap biotech looks well-positioned to deliver market-beating returns over the long run. 10 stocks we like better than Exelixis › A decade ago, shares of Exelixis (NASDAQ: EXEL), a biotech company specializing in oncology, were trading for under $10 per share. Today, the drugmaker's shares are changing hands for about $45 apiece. In other words, Exelixis has crushed the market since 2015. Some might think there is little upside left for the stock after this run, but that's not the case. Read on to find out why Exelixis still has plenty of growth fuel left in the tank. EXEL Total Return Level data by YCharts. Cabometyx is still doing the heavy lifting Exelixis is best known for its cancer medicine, Cabometyx. First approved in the U.S. in 2016 for patients with renal cell carcinoma (RCC, a form of kidney cancer), it was a bit of a breakthrough as the first therapy to show significant improvements for RCC patients in three important measures: overall survival, progression-free survival, and objective response rate (the percentage of patients who respond to treatment). Cabometyx has since earned numerous label expansions, and it continues to help drive solid top- and bottom-line growth for Exelixis. In the first quarter, the company's revenue jumped by 30.6% year over year to $555.4 million. The company's adjusted earnings per share (EPS) more than tripled to $0.62. Cabometyx has proven to be a successful pipeline drug, becoming the most prescribed tyrosine kinase inhibitor (a type of cancer drug that targets and kills cancer cells) among RCC patients, while making headway in hepatocellular carcinoma (liver cancer) and other markets. Despite Cabometyx's success, though, Exelixis will need more to continue delivering above-average returns over the long run. Generic competition for the medicine is expected to enter the U.S. market by 2030. Thankfully, Exelixis is already preparing for that eventuality. The next stage of growth Exelixis aims to apply the same blueprint that has made it successful over the past decade: developing a cancer medicine that can become a standard of care in a niche with a high unmet need, while earning label expansions in many other markets. The company appears to have already discovered its next gem. Exelixis recently reported positive top-line phase 3 results for zanzalintinib in patients with metastatic colorectal cancer (CRC). Despite having a high 5-year survival rate when caught early, CRC is the second-leading cause of cancer death worldwide partly because, once it has metastasized, there are few effective treatment options. Exelixis is looking to change that with zanzalintinib, and the company's apparent phase 3 success suggests it might be able to pull it off. Furthermore, zanzalintinib is being investigated across other indications, including those where Cabometyx is dominant, such as RCC. The former seems to have a better safety profile than its predecessor, among several other advantages. Beyond RCC and CRC, Exelixis plans to start several other late-stage studies for its next crown jewel this year, all of which will test it against current standards of care. As they say, to be the best, you have to beat the best. That's what Exelixis aims to do with zanzalintinib. Exelixis expects zanzalintinib to generate about $5 billion in sales eventually, far exceeding Cabometyx's current total or, for that matter, Exelixis' annual revenue. There is still some work to be done to get there, but early signs suggest that zanzalintinib is an excellent candidate. Exelixis' recent clinical progress also reinforces its leadership in oncology. The biotech company has several other early-stage candidates in development that could help it move beyond Cabometyx once it starts facing generic competition. Can Exelixis get to $200? From its current stock price of approximately $45, Exelixis needs a compound annual growth rate (CAGR) of at least 16.1% to reach $200 within the next decade and 10.5% to achieve this in 15 years. The former goal is ambitious, but the stock has delivered even better returns than that over the past decade. Although the past is no guarantee of future success, Exelixis' MO has remained the same and could, once again, allow it to generate monster returns over the long run as it makes significant clinical and regulatory progress with zanzalintinib and other pipeline candidates. Even if it falls short of this goal, though, my view is that Exelixis is well-positioned to deliver market-beating returns to patient investors -- the 15-year path to $200 would still be impressive. Either way, the stock looks like a buy. Should you invest $1,000 in Exelixis right now? Before you buy stock in Exelixis, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Exelixis wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025
Globe and Mail
an hour ago
- Globe and Mail
Is Nvidia Stock Too Expensive to Buy Now?
Key Points Data center growth is slated to continue for some time. Nvidia's GPUs are unrivaled in the AI space. Many stocks trade at the same price tag as Nvidia with far less growth. 10 stocks we like better than Nvidia › Nvidia (NASDAQ: NVDA) has been the top artificial intelligence (AI) stock to own for some time now, but with its latest rise, many investors are concerned that Nvidia's stock is too expensive to buy more shares at the current price. While I understand the hesitation, I think there is a compelling argument that Nvidia isn't expensive when you take a longer view than just a single year. If you can commit to owning Nvidia stock for three to five years, I think there's a good reason to buy the stock right now. However, if you're only looking at a single year, the stock may appear somewhat pricey. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » Data center expansion will continue to be a massive source of growth Nvidia is the global leader in graphics processing units (GPUs), and it has established this position through superior hardware and unmatched software that allow users to optimize GPUs for various workloads. One estimate pegs Nvidia's data center market share for GPUs at 90%, which underscores just how widely used Nvidia's products are. GPUs aren't just popular for AI workloads; they're used whenever an arduous computing task is involved. Whether it's drug discovery, cryptocurrency mining, engineering simulations, or their original purpose, gaming graphics, GPUs excel at the task because of their ability to process multiple calculations in parallel. Combine that with the ability to connect GPUs in clusters, and their computing power can be quickly amplified. As more data centers are built, the demand for GPUs is expected to rise, which will likely benefit Nvidia's stock over the long term. For 2025, the AI hyperscalers all announced record capital expenditures, with most of the funds going toward data center construction. While this is impressive, the records are likely to be shattered again in 2026, as data center construction spans multiple years. This supports a third-party projection that Nvidia cited during its 2025 GTC conference, stating that 2024 global data center capital expenditures totaled $400 billion but are expected to rise to $1 trillion by 2028. Should that occur, Nvidia's stock has plenty of room to run, as it captures a large portion of that spending. In the company's fiscal-year 2025 (which encompasses most of 2024), its data center revenue totaled $115 billion, which means Nvidia captures nearly 30% of total data center spending. If it can maintain that market share, it has the potential to generate $300 billion from data centers alone, provided the projection comes true. That's a significant upside from today's totals, making today's stock price appear less expensive than it initially seems. Nvidia's stock appears expensive, but so do many others in the market Currently, Nvidia's stock trades at about 40 times forward earnings. NVDA PE Ratio (Forward) data by YCharts That's historically quite expensive, but few companies have been able to sustainably grow as quickly as Nvidia. For Q2, Nvidia expects 50% revenue growth, which is far more than the majority of companies in the market. Furthermore, if you're going to call Nvidia expensive, then there are countless other stocks investors must be cautious with. Stocks like Amazon (NASDAQ: AMZN) (36 times forward earnings), Eli Lilly (NYSE: LLY) (35 times forward earnings), and Costco Wholesale (NASDAQ: COST) (53 times forward earnings) are just as expensive as Nvidia, yet don't have near the growth rate or upside. NVDA PE Ratio (Forward) data by YCharts I think it's safe to say that the broader market is rather expensive as a whole, but with how rapidly Nvidia is growing and how bright its long-term prospects are, I think investors are still safe to pick up shares here, as long as they have the mindset that they're holding for three to five years. If you can keep that time frame in mind, Nvidia is still a compelling investment. Should you invest $1,000 in Nvidia right now? Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025
